
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc. is positioned favorably in the biopharmaceutical sector, especially with its lead product PEMGARDA achieving emergency use authorization, which demonstrates regulatory validation and market readiness for its monoclonal antibody therapies. The company's engagement in a Phase 3 program (REVOLUTION) for VYD2311 is significant, as it could expand the target market substantially and provide evidence of mAb superiority over traditional mRNA vaccines, addressing a large population of immunocompromised individuals. Furthermore, the ongoing developments in next-generation antibody candidates and the potential revenue opportunities in the substantial COVID-19 vaccine market underscore Invivyd's prospects for growth in addressing viral infectious diseases.
Bears say
The analysis highlights fundamental concerns regarding Invivyd Inc's market potential, particularly due to the significant reduction in the efficacy of its leading monoclonal antibody therapy, PEMGARDA, against the omicron variant as evidenced by a 200-fold decline in activity observed during the STAMP trial. Furthermore, the company faces a challenging commercial landscape characterized by plummeting vaccination rates for COVID-19 and influenza, which may diminish demand for its therapies targeting immunocompromised individuals. As vaccine hesitancy persists and overall market opportunities narrow, Invivyd's financial outlook appears increasingly precarious.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares